Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells $35,139.08 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 74,764 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $0.47, for a total transaction of $35,139.08. Following the completion of the sale, the director now directly owns 3,840,146 shares in the company, valued at $1,804,868.62. This represents a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

IVVD opened at $0.44 on Friday. The business has a fifty day simple moving average of $0.78 and a 200 day simple moving average of $1.01. Invivyd, Inc. has a 1 year low of $0.40 and a 1 year high of $5.20. The company has a market capitalization of $53.10 million, a PE ratio of -0.23 and a beta of 0.53.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Morgan Stanley decreased their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Invivyd in a report on Thursday, November 21st. Finally, HC Wainwright decreased their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Invivyd currently has an average rating of “Buy” and a consensus target price of $7.89.

Hedge Funds Weigh In On Invivyd

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd increased its holdings in shares of Invivyd by 68.1% during the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the period. SG Americas Securities LLC raised its holdings in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after acquiring an additional 25,201 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in shares of Invivyd during the 3rd quarter valued at $27,000. Marshall Wace LLP grew its holdings in shares of Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares in the last quarter. Finally, State Street Corp increased its position in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the period. 70.36% of the stock is currently owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.